Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its stake in Insmed Incorporated (NASDAQ:INSM) by 9.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,839 shares of the biopharmaceutical company’s stock after purchasing an additional 6,691 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of Insmed worth $5,215,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. EntryPoint Capital LLC acquired a new position in Insmed during the 1st quarter worth approximately $33,000. Fidelis Capital Partners LLC purchased a new position in shares of Insmed in the first quarter valued at $34,000. First Horizon Advisors Inc. grew its holdings in Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 287 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Insmed during the 1st quarter worth $59,000. Finally, CWM LLC lifted its holdings in Insmed by 11.0% in the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of analyst reports. Truist Financial dropped their target price on Insmed from $88.00 to $85.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $55.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, June 20th. Bank of America reiterated a “buy” rating and set a $83.00 price objective on shares of Insmed in a research note on Friday, July 5th. TD Cowen boosted their target price on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Wells Fargo & Company increased their price target on shares of Insmed from $55.00 to $77.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 29th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.40.

Insmed Trading Down 1.0 %

NASDAQ:INSM opened at $74.21 on Friday. The firm has a market capitalization of $11.03 billion, a P/E ratio of -14.19 and a beta of 1.11. The business has a 50 day simple moving average of $74.68 and a 200 day simple moving average of $52.04. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. During the same period last year, the business posted ($1.78) earnings per share. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. Equities research analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.